---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-091945"
form_type: "8-K"
ticker: null
cik: "0001785173"
company_name: "89bio, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:29:19.623589+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 89bio enters $135M agreement with BiBo to build pegozafermin production facility

## Summary
- Collaboration agreement with BiBo to construct a production facility for pegozafermin commercial supply.
- 89bio to pay $135M total; 45% due in Q3 2024, remainder on milestone achievements.
- Facility located in Lin-gang Special Area, Shanghai Pilot Free Trade Zone.
- Work order for commercial supply under existing MSA expected before facility operations.
- Negotiated discount on commercial supply until payment recouped.

## SEC filing metadata
- accession: 0001193125-24-091945
- form_type: 8-K
- cik: 0001785173
- company_name: 89bio, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/0001193125-24-091945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/d818064d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-091945
- JSON: https://secwatch.observer/filing/0001193125-24-091945.json
- Plain text: https://secwatch.observer/filing/0001193125-24-091945.txt

## Key facts
- Material Agreements
  89bio, Inc. entered into Collaboration Agreement with BiBo Biopharma Engineering Co., Ltd. valued at $135 million (effective 2024-04-04).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: BiBo Biopharma Engineering Co., Ltd.
  - Value: $135 million
  - Effective: 2024-04-04
  source text: On April 4, 2024, 89bio, Inc., a Delaware corporation (the “Company”), entered into a collaboration agreement (the “Collaboration Agreement”) with BiBo Biopharma Engineering Co., Ltd., a company incorporated under the laws of the People’s Republic of China (“BiBo”), pursuant to which BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved (the “Production Facility”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/0001193125-24-091945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.